Mr. Arun Menawat reports

PROFOUND MEDICAL CONGRATULATES TEXAS PROSTATE ON ACHIEVING 100TH TULSA PROCEDURE MILESTONE

Texas Prostate, led by Dr. James Cochran, has achieved its 100th Tulsa procedure (using Profound Medical Corp.'s Tulsa-Pro system) performed in Dallas Medical Center's state-of-the-art MRI suite.

"Having performed hundreds of focal HIFU [high-intensity focused ultrasound] procedures for prostate cancer patients, we switched to primarily offering the Tulsa procedure because its unique MRI [magnetic resonance imaging] guidance and thermography allow us to treat a much broader range of prostate diseases, sizes, severities and aggressions, with an improved safety profile. With Tulsa, by planning and delivering therapy under continuous, in-bore MRI visualization -- rather than relying on diagnostic images obtained weeks or months earlier and aligned indirectly at the time of treatment in the case of HIFU -- we gain a clearer, more accurate understanding of tumour location and extent, enabling more precise and safer therapy," said Dr. Cochran. "Almost immediately upon transitioning from a private pay to a Medicare model via our new collaboration with Dallas Medical Center, our Tulsa procedure numbers increased by 500 per cent and continue to grow as new enquiries from around Texas and surrounding states come in every day and urologists in the Dallas-Fort Worth metroplex reach out to learn how to offer Tulsa to their patients."

"Under this innovative model pioneered by Texas Prostate -- bridging private-pay practices and Medicare-participating hospitals -- Dr. Cochran is demonstrating a way for urologists to accelerate adoption of the next generation of prostate care by allowing more men to benefit from the Tulsa procedure's versatility across the full spectrum of prostate disease," commented Arun Menawat, Profound's chief executive officer and chairman. "On behalf of everyone at Profound, we would like to congratulate Dr. Cochran and his team on his first 100 Tulsa procedures."

The Tulsa procedure, performed using the Tulsa-Pro system, represents a major advancement in prostate care and is used by physicians to treat men with prostate cancer and/or benign prostatic hyperplasia (BPH, also known as an enlarged prostate). Robotically controlled directional ultrasound is delivered from inside the urethra to precisely and gently heat prostate tissue to kill temperature (55 to 57 C) while protecting surrounding nerves and anatomy. Real-time MRI thermography enables continuous visualization and autonomous temperature adjustment throughout the procedure. This level of precision allows physicians to tailor therapy to each patient, resulting in no procedural blood loss, no overnight hospital stay and a quicker return to everyday life while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control and patient outcomes. By leveraging real-time MRI guidance, Profound's technologies are designed to replace uncertainty with clarity across treatment planning, delivery and confirmation.

The company's flagship platform, Tulsa-Pro, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The Tulsa procedure allows physicians to see, treat and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care -- from whole-gland to subtotal, hemi, multifocal and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumours and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay and faster recovery and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical's technologies are approved across major global markets. Tulsa-Pro is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand and the United Arab Emirates, while Sonalleve is cleared or approved in the United States (humanitarian device exemption), Europe, Canada, China and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy -- expanding access to precise, personalized and incision-free treatment options around the world.

We seek Safe Harbor.